Abstract
Background: The blood pressure-independent renoprotective actions of the blockade of the renin-angiotensin and the sympathetic nervous system are well documented, but monotherapies fail to completely abrogate progression. We investigated whether combined inhibition of the two systems provides additive renoprotection. Methods: After subtotal nephrectomy (SNX) or sham operation, rats underwent resection of dorsal roots, i.e. rhizotomy or sham rhizotomy. Subsequently, they received tap water or quinapril in drinking water for 16 weeks (n = 18/group). Albuminuria, blood pressure and kidneys were assessed (morphometry, immunohistochemistry). Results: At the end of the study telemetric blood pressure in SNX was 118 ± 16 mm Hg, in SNX + rhizotomy 110 ± 10 mm Hg, in SNX + quinapril 103 ± 9 mm Hg and in SNX + quinapril + rhizotomy 95 ± 7 mm Hg. Albuminuria in the respective groups was 169 ± 75, 86 ± 45, 15 ± 23 and 5 ± 4 mg/24 h. The glomerulosclerosis index was 1.40 ± 0.6, 0.80 ± 0.23, 0.37 ± 0.16 and 0.31 ± 0.15 (p < 0.001). Only combined intervention caused significant reduction of the glomerular volume and podocyte hypertrophy. The lowest indices for nitrotyrosine, NOS-1 (nNOS), TGF-β and interstitial collagen were seen with combined interventions (p < 0.05). Conclusion: In angiotensin-converting enzyme inhibitor-treated SNX animals, abrogation of sympathetic overactivity provides additional renoprotection and less nitro-oxidative stress of podocytes than single interventions. The added benefits were partially blood pressure independent.
Journal Section:
Original Paper
References
1.
Rennke HG, Klein PS: Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis 1989;13:443–456.
[PubMed]
2.
Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448–1456.
[PubMed]
3.
Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
[PubMed]
4.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–1462.
[PubMed]
5.
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
[PubMed]
6.
Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995;25:878–882.
[PubMed]
7.
Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002;15:717–724.
[PubMed]
8.
Amann K, Rump LC, Simonaviciene A, et al: Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000;11:1469–1478.
[PubMed]
9.
Amann K, Koch A, Hofstetter J, et al: Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001;60:1309–1323.
[PubMed]
10.
Rump LC, Oberhauser V: Chronic renal failure – taming the sympathetic nervous system! New approach to delaying progression. MMW Fortschr Med 1999;141:39–41.
[PubMed]
11.
Hostetter TH: The next treatments of chronic kidney disease: if we find them, can we test them? J Am Soc Nephrol 2002;13:3024–3026.
[PubMed]
12.
Benigni A, Zoja C, Corna D, et al: Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003;14:1816–1824.
[PubMed]
13.
Schwarz U, Amann K, Orth SR, et al: Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53:1696–1705.
[PubMed]
14.
Bunag RD: Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 1973;34:279–282.
[PubMed]
15.
Magnotti RA Jr, Stephens GW, Rogers RK, Pesce AJ: Microplate measurement of urinary albumin and creatinine. Clin Chem 1989;35:1371–1375.
[PubMed]
16.
el Nahas AM, Zoob SN, Evans DJ, Rees AJ: Chronic renal failure after nephrotoxic nephritis in rats: contributions to progression. Kidney Int 1987;32:173–180.
[PubMed]
17.
Kang DH, Hughes J, Mazzali M, et al: Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001;12:1448–1457.
[PubMed]
18.
Amann K, Nichols C, Tornig J, et al: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996;11:1003–1011.
[PubMed]
19.
Torry RJ, Connell PM, O’Brien DM, et al: Sympathectomy stimulates capillary but not precapillary growth in hypertrophic hearts. Am J Physiol 1991;260:H1515–H1521.
20.
Skov K, Nyengaard JR, Patwardan A, Mulvany MJ: Large juxtamedullary glomeruli and afferent arterioles in healthy primates. Kidney Int 1999;55:1462–1469.
[PubMed]
21.
Culy CR, Jarvis B: Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 2002;62:339–385.
[PubMed]
22.
Orth SR, Amann K, Strojek K, Ritz E: Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant 2001;16(suppl 1):67–69.
[PubMed]
23.
Lohmeier TE: The sympathetic nervous system and long-term blood pressure regulation. Am J Hypertens 2001;14:147S–154S.
24.
LeNoble LM, Lappe RW, Brody MJ, et al: Selective efferent chemical sympathectomy of rat kidneys. Am J Physiol 1985;249:R496–R501.
25.
Szenasi G, Bencsath P, Szalay L, Takacs L: Fasting induces denervation natriuresis in the conscious rat. Am J Physiol 1985;249:F753–F758.
26.
Neumann J, Ligtenberg G, Oey L, et al: Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004;15:2902–2907.
[PubMed]
27.
Vonend O, Marsalek P, Russ H, et al: Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003;21:1709–1717.
[PubMed]
28.
Strojek K, Grzeszczak W, Gorska J, et al: Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001;12:602–605.
[PubMed]
29.
Rosenberg ME, Hostetter TH: Comparative effects of antihypertensives on proteinuria: angiotensin-converting enzyme inhibitor versus alpha 1-antagonist. Am J Kidney Dis 1991;18:472–482.
[PubMed]
30.
DiBona GF: Neural control of the kidney: past, present, and future. Hypertension 2003;41:621–624.
[PubMed]
31.
DiBona GF: The sympathetic nervous system and hypertension: recent developments. Hypertension 2004;43:147–150.
[PubMed]
32.
Boivin V, Jahns R, Gambaryan S, et al: Immunofluorescent imaging of beta 1- and beta 2-adrenergic receptors in rat kidney. Kidney Int 2001;59:515–531.
[PubMed]
33.
Durvasula RV, Petermann AT, Hiromura K, et al: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004;65:30–39.
[PubMed]
34.
Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993;92:1366–1372.
[PubMed]
35.
Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431–2437.
[PubMed]
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
